跳至主要内容
临床试验/NCT04541771
NCT04541771Unknown2 期

The Role of Lactobacillus Reuteri (L. Reuteri) in Preventing Necrotizing Enterocolitis (NEC) in Pre-term Infants Less Than 34 Weeks of Gestation

Children's Hospital and Institute of Child Health, Multan0 个研究点目标入组 120 人开始时间: 2020年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
发起方
入组人数
120
主要终点
narcotizing enterocolitis

研究概览

简要总结

The purpose of this study is to compare the effectiveness of L. Reuteri with placebo in prevention of NEC in children, as according to my knowledge, there is limited work is done nationally and internationally. Probiotics are being used in our Children Hospital and the Institute of Child Health, Multan.

Route of administration of L. Reuteri will be oral or via nasogastric tube due to availability of oral form in Pakistan. The results of this study will be helpful to assess the beneficial effects of probiotics especially L. Reuteri in NEC in preterm. So, they can be recommended as preventive strategy to avoid NEC development and its complications based on its availability, effectivity and easy administration

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
28 Weeks 至 34 Weeks(Child)
性别
All
接受健康志愿者

入选标准

  • Preterm neonate< 34 weeks and >28 weeks of gestation of both genders Hemodynamically stable

排除标准

  • Preterm neonates >34 weeks gestational age < 28 weeks of gestation Cardiorespiratory illness Parental refusal

研究组 & 干预措施

drug group

Experimental

The trial group will receive their usual feeds plus daily probiotic (Lactobacillus Reuteri DSM 17938) addition 1 drop/kg/dose(. minimum of 20 million live Lactobacillus Reuteri are present in One drop) twice daily added in expressed breast milk/formula milk from the beginning of enteral feedings till the baby attain full feeds

干预措施: Lactobacillus Reuteri DSM 17938 (Drug)

control group

Placebo Comparator

this group is control group and will receive normal saline drops as 1 drop/kg/ dose mixed in enteral feed

干预措施: Placebo (Drug)

结局指标

主要结局

narcotizing enterocolitis

时间窗: up to 35 weeks of gestation

number of participants with the sign of feeding intolerance (such as the gastric aspirate in the amount that was more than half of previous feeding), or with abdominal distension measured by increase in abdominal girth from base line,Bell Staging Criteria according to clinical and radio-logical signs

次要结局

  • sepsis(At time of addmission and 15 days after intervention)

研究者

发起方
Children's Hospital and Institute of Child Health, Multan
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Dr Summera Tabasum

post-graduate resident

Children's Hospital and Institute of Child Health, Multan

相似试验